Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15324510 | 0.93 | KDM4E (0.47) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL15323608 | 0.85 | KDM4E (0.53) | KDM4EMAPTMGLL | |
| SCHEMBL15324835 | 0.81 | MAPT (0.45) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL15324833 | 0.81 | MAPT (0.45) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL15324505 | 0.78 | MAPT (0.48) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL15324508 | 0.78 | MAPT (0.48) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL6046338 | 0.76 | MAPT (0.57) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL6046337 | 0.76 | MAPT (0.57) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL16589520 | 0.74 | BCHE (0.43) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL15322919 | 0.73 | MTNR1A (0.52) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499484-B2 | Indole, indoline derivatives, compositions comprising them and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-11-22 | — | — | US | disclosed |
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2015-03-26 | — | — | US | disclosed |
| EP-2847165-A2 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013150529-A2 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | IDO1, INMT, IDO2 | KDM4E 973/4885MEN1 2212/4885MAPT 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.